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Abstract
Background: Retained placenta is one of the common causes of maternal mortality in developing countries
where access to appropriate obstetrical care is limited. Current treatment of retained placenta is manual removal
of the placenta under anaesthesia, which can only take place in larger health care facilities. Medical treatment of
retained placenta with prostaglandins E1 (misoprostol) could be cost-effective and easy-to-use and could be a life-
saving option in many low-resource settings. The aim of this study is to assess the efficacy and safety of sublingually
administered misoprostol in women with retained placenta in a low resource setting.
Methods: Design: Multicentered randomised, double-blind, placebo-controlled trial, to be conducted in 5
hospitals in Tanzania, Africa.
Inclusion criteria: Women with retained placenta, at a gestational age of 28 weeks or more and blood loss less
than 750 ml, 30 minutes after delivery of the newborn despite active management of third stage of labour.
Trial Entry & Randomisation & Study Medication: After obtaining informed consent, eligible women will be
allocated randomly to the treatment groups using numbered envelopes that will be randomized in variable blocks
containing identical capsules with either 800 microgram of misoprostol or placebo. The drugs will be given
sublingually. The women, maternal care providers and researchers will be blinded to treatment allocation.
Sample Size: 117 women, to show a 40% reduction in manual removals of the placenta (p = 0.05, 80% power).
The randomization will be misoprostol: placebo = 2:1
Primary Study Outcome: Expulsion of the placenta without manual removal. Secondary outcome is the number
of blood transfusions.
Discussion: This is a protocol for a randomized trial in a low resource setting to assess if medical treatment of
women with retained placenta with misoprostol reduces the incidence of manual removal of the placenta.
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Published: 23 October 2009
BMC Pregnancy and Childbirth 2009, 9:48 doi:10.1186/1471-2393-9-48
Received: 5 July 2009
Accepted: 23 October 2009
This article is available from: http://www.biomedcentral.com/1471-2393/9/48
© 2009 van Beekhuizen et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 6
(page number not for citation purposes)
BMC Pregnancy and Childbirth 2009, 9:48 http://www.biomedcentral.com/1471-2393/9/48Background
Retained placenta: diagnosis, definition and the burden of 
disease
The diagnosis 'retained placenta' (RP) is established when
the placenta is not expelled after a certain time period fol-
lowing the delivery of the infant[1,2]. The time period in
the definition of RP varies among countries. In our study
location Tanzania, like most English speaking countries,
RP is defined as lack of expulsion of the placenta 30 min-
utes after delivery of the infant [3], while in other coun-
tries the diagnosis RP is only made after 60 minutes
postpartum [4]. Complications of RP are postpartum
haemorrhage and infection[5], which may both lead to
maternal morbidity and mortality. The need to improve
maternal mortality has been recognized at a global level
by including it in the Millennium Development Goals [6].
Tanzania is a low resource country with a high maternal
mortality rate. It is estimated that 578 women per
100,000 live-births die as a result of pregnancy-related
complications [7]. A retrospective study in Tanzania
showed that RP contributed by 13% to the maternal
deaths [8]. The morbidity due to RP is mainly caused by
infections and anaemia. A study by Tandberg et al found
a significant fall in haemoglobin level postpartum com-
pared to antepartum by a mean of 3.4 g/dl (2.1 mmol/l)
in the RP group as compared to no significant change in
the controls; blood transfusion was required in 10% of
the RP group versus 0.5% in the control group [9].
Retained Placenta: incidence
The incidence of RP is approximately 1-2% of all deliver-
ies worldwide, the exact data for Tanzania is not known.
The reported incidence of RP is affected by the following
four factors: definition of the time interval [4], gestational
age, an obstetrical history of previous RP or not, and the
presence or absence of active management of the third
stage of labour (AMTSL).
The incidence of RP in an unselected group of nulliparous
women in The Netherlands was 6.3% at 30 minutes and
1.8% at 60 minutes after delivery of the newborn [4]. The
incidence of RP, 30 minutes after delivery of the newborn
has been reported as 8% in preterm and 1.1% in term
deliveries [10]. The recurrence risks of RP reported in two
studies of parous women were 16% and 23% [9,11]. A
randomized controlled trial (RCT) showed that AMTSL
reduced the incidence of RP (after 30 minutes) to 1.6% as
compared to 4.6% in the control group [12].
Retained placenta: how can we prevent maternal 
mortality?
Blood loss associated with RP can be acute life-threaten-
ing and requires emergency interventions like administra-
tion of uterotonics, correction of hypovolaemia by
administration of intravenous fluids, manual removal of
the placenta (MRP) under anaesthesia and blood transfu-
sions[13]. All these interventions need skilled personnel
and equipment. In many low-resource countries women
deliver at home, and the nearest health care facility often
lacks drugs and equipment to perform MRP or to give
blood transfusion, leaving the midwife empty-handed.
Transport to health care facilities with comprehensive
emergency obstetrical care requires time and money, both
are limited commodities in those circumstances [6,8].
Medical treatment of RP with an easy-to-administer drug
could save the life of patients under those circumstances.
Retained placenta: medical treatment with prostaglandin 
analogues
Medical treatment of RP includes the administration of
oxytocin in the umbilical vein, which was reported to be
effective in one out of eight women (relative risk 0.79,
95% CI 0.69-0.91) [14]. The disadvantage of this method
in low resource settings is that it requires skilled medical
personnel and equipment.
A RCT in The Netherlands showed that administration of
250 microgram prostaglandin E2 (sulprostone) intrave-
nously 60 minutes after delivery of the infant effectively
expelled 49% of RP versus 11% in the placebo group [15]
within 60 minutes after administration. Blood loss was
388 ml lower in the sulprostone group (average blood
loss 1062 ml) as compared to controls (average blood loss
1450 mls). Unfortunately, treatment with sulprostone is
not applicable in low resources settings because the drug
is relatively expensive and needs to be stored refrigerated.
The prostaglandin E1 analogue misoprostol is inexpen-
sive and does not need to be stored refrigerated. Therefore,
it is of potential use in low-resource countries. In a recent
study in which 54 patients with RP were randomised to
misoprostol, oxytocin and placebo, administered through
the umbilical cord [16], a significant reduction of MRP
was reported for the misoprostol (43% MRP) compared
to the oxytocin (80% MRP) and placebo (54% MRP)
groups. When misoprostol was administered rectally in a
group of 10 patients [17], it was reported to avoid MRP in
7 patients and to reduce blood loss. Oral or sublingual
administration of misoprostol, though potentially the
fastest acting [18] and most practical, has not been stud-
ied in an effort to reduce MRP.
Misoprostol
Misoprostol is an prostaglandin E1-analogue with uterot-
onic properties that can be administered orally, sublin-
gually, vaginally and rectally [19]. Sublingual
administration of misoprostol achieves the highest serum
peak concentration and takes the shortest time to reach
the peak level, in comparison with other routes of admin-Page 2 of 6
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temperature. Originally, misoprostol was introduced as
treatment for peptic ulcers. It soon became obvious that it
stimulates uterine contractions [20]. Misoprostol has
been used to treat various obstetrical problems, including
uterine atony, postpartum haemorrhage [21], induction
of labour, and induction of abortion [19,20]. Misoprostol
when given postpartum is known to cause only mild side
effects (shivering and pyrexia) [19,22-24]. Misoprostol is
a sustainable drug for use in developing countries for the
treatment of various obstetrical complications [20] like
postpartum haemorrhage, induction of labour and induc-
tion of abortion. It is registered in Tanzania for the pre-
vention and treatment of postpartum haemorrhage.
Study justification
Women in rural areas in resource-poor settings who
deliver at home or in a village health care facility, and in
whom the delivery is complicated by RP, have difficulty to
reach appropriate medical help in time and have a consid-
erable chance to die because from post partum hemor-
rhage. Because preliminary evidence suggests that
prostaglandins like misoprostol may expel the placenta
and reduce blood loss in women with RP, a RCT is
designed to compare sublingually administered misopr-
ostol with placebo to tests its effectiveness to reduce the
need of MRP and blood transfusion in a low-resource set-
ting.
Aims of the trial
The aims of this randomised, double blind, placebo-con-
trolled trial is to assess if sublingual misoprostol reduces
the need of Manual Removal of Placenta (MRP) and the
amount of blood loss in women with RP in a low resource
setting. The primary outcome variable is reduction in the
incidence of MRP and the secondary outcome variable is
the reduction in the number of units of packed cells
administered.
The primary hypothesis of this randomised trial is that the
administration of misoprostol to women with RP reduces
the number of women who need MRP. The secondary
hypothesis is that misoprostol reduces the amount of
blood loss in women with RP, especially in those in
whom the placenta is expelled by the intervention. Since
measurement of blood loss during delivery is not always
very reliable, we choose as secondary outcome variable
both the measured amount of blood loss and the number
of administered packed cells.
Methods/Design
Study Design
Multicentered randomised, double-blind, placebo-con-
trolled trial.
Participating hospitals & approval
The study will be conducted in four rural hospitals in
Southern Tanzania (the regional hospitals of Lindi and
Mtwara regions and Ndanda and Nyangao mission hospi-
tals) and in the university teaching hospital in the capital
Dar es Salaam. Approval for this study was obtained from
the National Institute of Medical Research (NIMR), the
Senate Research and Publication Committee of Muhim-
bili University of Health and Allied Sciences and the
Muhimbili National Hospital in Tanzania. A data man-
agement safety board has been installed.
Inclusion criteria and trial entry
All labouring women will receive AMTSL and are eligible
if 30 minutes after delivery of the infant the placenta has
not been expelled and were delivered of a baby of 1 kg or
more or at a gestational age of 28 weeks or more. AMTSL
is defined as administration of 5IU oxytocin and control-
led cord traction (CCT). If the placenta is delivered the
uterus will be massaged.
Exclusion criteria
Women with one of the following conditions will be
excluded from entering the trial:
• Haemoglobin concentration less than 100 g/l (6.2
mmol/l)
• Blood loss more than 750 ml
• Pulse rate more than 120 beats per minute
• Diastolic blood pressure reduction after delivery
more than 20 mmHg
Trial Entry
Eligible women will be identified in the labour ward at 20
minutes after delivery of the infant. The bladder will be
catheterised, an intravenous canula will be inserted and
normal saline solution will be started, CCT will be per-
formed again and blood will be taken for cross-match and
haemoglobin concentration. They will receive verbal and
written information in Kiswahili about participation in
the trial and will be asked to give their informed consent.
The randomisation schedule uses balanced variable
blocks; sealed envelopes containing both registration
form and blinded study medication are present in the
delivery room. Allocation will be in sequence of enrol-
ment in each of the five labour wards. Each sealed envelop
contains two identical capsules with either 800 micro-
gram misoprostol or placebo. The patient, the maternal
care providers and the researchers are all blinded to the
allocation. Women will enter the study after giving their
informed consent at 30 minutes following the delivery of
the infant, at which time the envelope will be opened andPage 3 of 6
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sublingually. Figure 1 depicts the flowchart for trial entry.
Study Medication & Treatment Schedules
After administration of the study medication, the doctor
or midwife will perform CCT every ten minutes to check
if the placenta has separated from the uterine wall. Vagi-
nal blood loss will be measured by weighing self absorb-
able mattresses. Blood loss exceeding 1500 ml will be
considered as indication for emergency MRP. If the pla-
centa is not expelled 30 minutes after the administration
of the study medication, the patient will undergo MRP.
Follow-up of women in both treatment groups
All women enrolled in the study are followed up for 12-
24 hours. Blood pressure, pulse rate uterine contraction
and vaginal blood loss are monitored, and the haemo-
globin concentration prior to discharge is recorded.
Women are receiving blood transfusion and and/or intra-
venous iron dextrane infusion, according to the hospitals
guidelines, if needed. All women receive combined ferro-
fumerate and folic acid tablets according to the national
guideline on care for post partum women.
Study Endpoints
The primary study outcome is:
• Manual removal of the placenta.
Flowchart for trial entryigure 1
Flowchart for trial entry. AMTSL = Active management of third stage of labour. RP = retained placenta. CCT = controlled 
cord traction. Hb = Haemoglobin. BP = Blood pressure. MRP = Manual removal of placenta. Hb = haemoglobine.
All women: AMSTL 
When RP 20 min: 
•Empty bladder and perform CCT 
•Check Hb & measure blood loss & insert i.v. canula 
•Ask informed consent 
If  
- Exclusion criteria present  
- Informed consent absent: 
 
Than MRP 
If  
- Exclusion criteria absent 
- Informed consent present; 
Than open envelope and administer 
study medication 30 minutes after 
delivery 
Check exclusion criteria:· 
- Haemoglobin < 100 g/l 
· Blood loss > 750 ml 
· Pulse rate > 120 
· Diastolic BP drop > 20 mmHg 
Placebo n= 39 Misoprostol n= 78 
Placenta expelled If placenta not expelled 60 min  
post delivery: MRP 
Placenta expelled 
 
If placenta not expelled 60 min  
post delivery: MRP 
 
CCT every 10 minutes 
 
If blood loss exceeds 1500 ml: 
Emergency MRP 
CCT every 10 minutes 
 
If blood loss exceeds 1500 ml: 
Emergency MRP 
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• Measured post partum blood loss,
• Number of units of blood administered,
• Adverse outcome for the woman, including side-
effects from the study medication and number of
emergency MRP needed.
Sample Size
The primary endpoint of the study is manual removal of
the placenta. For eligible women (with RP 30 minutes
after delivery of the infant) the best estimate of MRP is
44% at 60 minutes post partum. Using 2:1 misoprostol to
placebo randomisation, a sample size of 117 women will
be able to show a 40% reduction in MRP (5% level of sig-
nificance, two-tailed alpha, 80% power). Thus, 39
patients will receive placebo and 78 will receive misopros-
tol.
Analysis and Reporting of Results
Baseline characteristics of all women enrolled in the study
are documented and analysed in order to verify the
absence of confounding differences in baseline variables
between groups. Outcome comparisons for women will
be analysed according to 'intention to treat'. Relative risks
and 95% confidence intervals will be reported for the pri-
mary and secondary outcomes, and the number needed to
treat to prevent one MRP will be calculated. A data man-
agement safety board will check the data at regular inter-
vals.
Discussion
This is a protocol for RCT assessing the efficacy of sublin-
gual misoprostol in women with a RP 30 minutes after
delivery of the infant. The trial is conducted in a low-
resource setting in order to establish if misoprostol treat-
ment of RP reduces maternal morbidity associated with
retained placenta in such a setting. This study is partially
carried out in an environment where communication is
difficult and where people have little experience with con-
ducting research. During the research period we have to
anticipate unforeseen difficulties like breakdown of
equipment, loss of data or study medication and other
unpredictable events.
When the hypotheses of the study, that misoprostol
reduces the amount of MRP and blood loss, is confirmed,
it should have consequences for the basic obstetrical care
in rural health centres in developing countries. Misopros-
tol should then be made available to all health facilities
and staff should be trained in administering the drugs cor-
rectly.
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